IUPAC: (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol · C₁₇H₁₉NO₃ · MW 285.34 g/mol · CAS 57-27-2
Morphine. The prototype opioid — principal analgesic alkaloid of Papaver somniferum (opium poppy), isolated by Sertürner in 1804 and the yardstick against which every opioid is still measured. A rigid pentacyclic morphinan · full µ-opioid receptor agonist · the reference standard for opioid potency, tolerance, and respiratory depression. Context names: MS Contin, Kadian, Oramorph, "morph," "Miss Emma."
Morphine is a full agonist at the µ-opioid receptor (MOR / OPRM1), a class-A GPCR coupled to inhibitory Gi/o heterotrimers. Unlike the monoamine drugs in this series — which act on transporters (cocaine, MDMA) or bias serotonergic GPCRs (DMT) — morphine works by switching off neuronal excitability. It occupies the same orthosteric morphinan pocket used by the endogenous enkephalins/endorphins, collapses the receptor onto its active conformation, and recruits Gi/o to shut down adenylyl cyclase and gate ion channels.
The rigid phenanthrene core anchors via a salt bridge from the protonated tertiary amine to Asp1473.32, with the phenolic 3-OH hydrogen-bonding the His297/conserved water network — the same pocket resolved in the active-state µOR structure.
Activated Gαi/o inhibits adenylyl cyclase, dropping intracellular cAMP and PKA tone. Chronic agonism triggers compensatory AC superactivation — the molecular substrate of tolerance and withdrawal rebound.
Liberated Gβγ opens GIRK (Kir3) potassium channels, hyperpolarizing the neuron. This postsynaptic K⁺ efflux is the direct brake on firing — and, in brainstem respiratory neurons, the mechanism of apnea.
Gβγ also blocks N/P/Q-type voltage-gated Ca²⁺ channels presynaptically, cutting neurotransmitter release — including substance P and glutamate from primary nociceptive afferents in the dorsal horn.
Morphine recruits β-arrestin-2, driving receptor internalization and desensitization. β-arrestin-2 knockouts show enhanced analgesia with blunted respiratory depression/constipation — the (contested) rationale behind "biased" MOR agonists.
MOR sits on GABAergic interneurons of the ventral tegmental area. Silencing them disinhibits dopamine neurons, raising DA in the nucleus accumbens — the reinforcement signal underlying euphoria and dependence.
The net cellular effect is inhibitory across the pain neuraxis: morphine suppresses ascending nociceptive transmission in the spinal dorsal horn, activates descending inhibition from the periaqueductal grey (PAG) → rostral ventromedial medulla (RVM), and blunts the affective salience of pain in the limbic cortex. Analgesia, euphoria, respiratory depression, and constipation are all the same receptor acting in different circuits — which is exactly why the therapeutic and lethal effects cannot be cleanly separated.
Morphine's pharmacokinetics are dominated by hepatic glucuronidation via UGT2B7, not the CYP system. Extensive first-pass conjugation gives it a low, variable oral bioavailability (~20–40%, ≈25% typical) — the reason oral doses run several-fold higher than parenteral. The twist is that one of its two major metabolites is more active than the parent.
Metabolism cascade: Roughly 90% of a morphine dose is glucuronidated. The 3- and 6-glucuronides diverge sharply in pharmacology.
Morphine-6-glucuronide (M6G, marked ★) is a potent µ-opioid agonist in its own right — it crosses the blood–brain barrier slowly but contributes substantially to analgesia and respiratory depression on repeated dosing. Critically, M6G is renally cleared: in renal impairment it accumulates and can produce delayed, prolonged respiratory depression hours after the parent drug has cleared — a classic ICU trap.
Morphine-3-glucuronide (M3G) is the dominant metabolite (~55%) but is essentially inactive at MOR; it is implicated in neuroexcitatory phenomena (myoclonus, allodynia, hyperalgesia) at high cumulative exposure. UGT2B7 polymorphisms and co-administered UGT substrates shift the M3G:M6G ratio and thus both efficacy and toxicity.
Because a single receptor drives the whole syndrome, morphine's effects map cleanly onto where MOR is expressed. The subjective experience — analgesia plus anxiolysis, warmth, and detachment — is the limbic and cortical face of the same Gi/o inhibition that stops nociceptive traffic in the cord.
Dorsal-horn MOR cuts substance P / glutamate release from C-fibres and hyperpolarizes projection neurons; supraspinally, PAG→RVM descending inhibition is engaged. Morphine also uncouples the sensory intensity of pain from its affective unpleasantness via cingulate/insular MOR — patients report "the pain is still there but it doesn't bother me."
Disinhibition of VTA dopamine neurons raises accumbens DA, producing the initial rush and reinforcing use. Repeated activation drives neuroadaptation (AC superactivation, ΔFosB) that underlies tolerance, dependence, and — on cessation — a noradrenergic-driven withdrawal storm centred on the locus coeruleus.
MOR on rhythm-generating neurons of the pre-Bötzinger complex and the parabrachial/Kölliker-Fuse nuclei blunts both respiratory rate and the CO₂ chemoreflex. This is dose-dependent, not idiosyncratic, and is the mechanism of every opioid death: breathing simply slows and stops. Sleep and CNS depressants remove the arousal safety net.
Enteric MOR produces near-universal constipation (minimal tolerance develops — hence stimulant laxatives are standard). Edinger-Westphal engagement gives pinpoint miosis, a key overdose sign. Morphine also triggers non-immune mast-cell histamine release (itch, flush, hypotension), distinguishing it from synthetic opioids like fentanyl.
Clinically morphine remains a WHO Essential Medicine and the backbone of severe acute, cancer, and end-of-life pain management. Its liabilities are not moral failings of the molecule — they are the direct pharmacology of MOR, and every one of them (analgesia, euphoria, apnea, constipation) reverses with a competitive antagonist.
Evidence-based, non-moralistic. Opioid deaths are respiratory deaths — they are predictable, dose-dependent, and reversible if caught in time. Information and naloxone save lives; shame does not.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
µ / MOR
Mu-opioid receptor (OPRM1)
|
Ki ≈ 1.8 nM
median 2.6 · range 0.14–38
|
Full agonist | |
|
κ / KOR
Kappa-opioid receptor (OPRK1)
|
Ki ≈ 64 nM
median ~60 · range 6.9–299
|
Partial agonist | |
|
δ / DOR
Delta-opioid receptor (OPRD1)
|
Ki ≈ 140 nM
median ~150 · range 51–710
|
Weak agonist |
Morphine is a striking case study for the thermodynamics FlexAID∆S is built to resolve. Binding free energy decomposes as ΔG = ΔH − TΔS, and the entropy term splits into a ligand conformational component and a receptor/solvent component. Most drug-like ligands pay a stiff entropic penalty on binding: freezing rotatable bonds into a single bound rotamer is a Shannon-entropy collapse over the torsional ensemble, and it costs free energy.
Morphine barely pays it. Its pentacyclic morphinan cage has zero rotatable bonds (ChEMBL: RTB = 0) — the pharmacophore is pre-organized. The protonated amine, the phenolic 3-OH, and the aromatic ring are locked in the geometry the µOR orthosteric pocket wants before it ever docks. In entropy terms the ligand's torsional distribution is already a delta function; there is almost no configurational information to destroy on binding, so −TΔSlig ≈ 0 and the intrinsic affinity (Ki ≈ 1–3 nM) is bought cheaply. This is the mirror image of flexible opioids like fentanyl, which trade a larger entropic cost for enthalpic contacts.
The receptor side tells the complementary story. Agonist binding collapses the µOR conformational ensemble onto the active state — the outward swing of TM6, the rotamer toggle of the conserved Trp6.48 "toggle switch," and the rearranged NPxYY motif captured in 5C1M. That is a genuine entropy reduction in the protein, and it is exactly the quantity a physics-grounded docking score must model rather than hand-wave: affinity is not enthalpy alone, it is the balance of enthalpy against how much conformational entropy each partner surrenders. Morphine wins by surrendering almost none of its own — a first-principles reason a 200-year-old poppy alkaloid still out-binds most things we design.